Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...

The Decipher Prostate test is already widely used in the US to help identify localised prostate cancer more likely to spread. It becomes the first molecular test with clinical evidence from a ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

Leveraging Electronic Health Record Tools and Social Work to Improve Advance Care Planning Documentation in Older Adults With Cancer Their investigation was a study imbedded in a randomized trial ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...